Generic Name: mytomycin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Chemotherapy Medications

Company: UroGen

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Jelmyto is an alkylating drug approved for the treatment of low-grade urothelial cancer in the upper urinary tract.

General Info

Jelmyto is an alkylating agent that binds to DNA and interferes with transcription factors that play a role in cancer cell growth. In the OLYMPUS trial, 58% of participants treated with Jelmyto experienced complete remission. Jelmyto was first approved in 1974.


Dosing Info:

Jemlyto is inserted into the urinary tract through a catheter once weekly for six weeks and then once monthly.

Side Effects

The most common adverse reactions include ureter obstruction, abdominal or flank pain, urinary tract infections, difficult urination, blood in the urine, kidney dysfunction, nausea and vomiting. Jelmyto can cause depletion of white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. It can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 29, 2020